Equities Analysts Issue Forecasts for ONCY Q1 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for Oncolytics Biotech in a report released on Friday, April 10th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.02) for the quarter. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at ($0.02) EPS, Q4 2027 earnings at ($0.02) EPS and FY2030 earnings at $0.18 EPS.

Oncolytics Biotech (NASDAQ:ONCY) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02).

Several other research analysts also recently commented on ONCY. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Friday, March 27th. Wall Street Zen upgraded shares of Oncolytics Biotech from a “strong sell” rating to a “hold” rating in a research report on Saturday, April 4th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Oncolytics Biotech Price Performance

NASDAQ ONCY opened at $0.93 on Monday. The stock’s 50-day moving average price is $0.97 and its 200-day moving average price is $1.04. Oncolytics Biotech has a 52 week low of $0.33 and a 52 week high of $1.51. The company has a market capitalization of $108.00 million, a P/E ratio of -3.21 and a beta of 0.98.

Institutional Trading of Oncolytics Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of ONCY. Citadel Advisors LLC bought a new stake in Oncolytics Biotech in the 3rd quarter valued at $535,000. Connective Capital Management LLC bought a new stake in Oncolytics Biotech in the 4th quarter valued at $131,000. XTX Topco Ltd bought a new stake in Oncolytics Biotech in the 4th quarter valued at $69,000. Virtu Financial LLC bought a new stake in Oncolytics Biotech in the 4th quarter valued at $68,000. Finally, Tocqueville Asset Management L.P. bought a new stake in Oncolytics Biotech in the 4th quarter worth approximately $63,000. 6.82% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Oncolytics Biotech news, insider Andrew Aromando bought 29,600 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were bought at an average price of $0.86 per share, with a total value of $25,456.00. Following the purchase, the insider owned 55,100 shares of the company’s stock, valued at $47,386. This trade represents a 116.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Patricia S. Andrews bought 35,400 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were acquired at an average cost of $0.86 per share, for a total transaction of $30,444.00. Following the purchase, the director directly owned 78,128 shares in the company, valued at $67,190.08. This trade represents a 82.85% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 404,282 shares of company stock worth $363,232 over the last quarter. Company insiders own 0.10% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.